go further

On-going investments in cell and gene therapy (CGT) fuel growth

As of 2020, 16 out of 20 of the largest biopharma manufacturers have added cell and gene therapies to their portfolios.[1]

>2,700

The number of CGT therapies in development as of April 2022

>$67.4B

The expected worth of the global CGT manufacturing market by 2030[2]

Evidera | PPD

1. Suryaprakash S, Teixeira A, Choy M. The Changing Landscape of Cell and Gene Therapy. Boston Consulting Group. May 5, 2021. Accessed October 10, 2022. https://www.bcg.com/publications/2021/understanding-the-rapidly-changing-cell-and-gene-therapy landscape. 2. Cell and Gene Therapy Manufacturing Market Size to Worth Around US%67.4 Bn by 2030. BioSpace. June 1, 2022. Accessed October 10, 2022. https://www.biospace.com/article/cell-and-gene-therapy-manufacturing-market-size-to-worth-around-us-67-4-bn-by-2030/?keywords=catalent.

Realize the potential of your CGT

The road ahead is complex and uncertain. PPD is here to help you overcome challenges and get ahead of unknowns—advancing your novel therapy across every aspect of the development life cycle. From early strategic development to value and access consultation, we can partner with you to help identify and operationalize your path forward.

130

clinical trials in the last 5 years

75

gene therapy clinical trials

adenovirus/AAV • lentivirus • retrovirus • virus-based immunotherapies

55

cell therapy clinical trials

CAR-NK cells • adoptive T-Cell • antigen-precenting cells • primitive stem cells

300

peri- & post-approval projects

value demonstration • market access • commercial strategy

20

years of bioanalytical lab GCT experiences

millions of samples analyzed • 300+ CGT assays • over 170 scientists and staff

Partner with the CRO that supported 100% of marketed transformative therapies.

Let's go →

Evidera | PPD

Novel solutions for novel therapies

To optimize success, you need a CRO that truly gets CGT drug development and is ready with solutions at every phase of the journey. Our comprehensive end-to-end CGT solutions support the distinct needs of patients, sites, and sponsors with the ease of working with a single partner.

	Clinical Development Services				Laboratory Services
Early Development	Strategic Development Consulting	Protocol Development	Pre-IND / IND Support	Pharmacology & Toxicology	Biomarker Lab Bioanalytical Lab
Phase I-IIIb	Site & Patient Recruitment	Data Management	Market Access Strategy	Biostatistics	Central Lab
Phase IV Peri- and Post-Approval	Data Analytics	Observational studies	PASS/PMRs	Evidence of value	GMP Lab

- Global Scale
- Breadth of Therapy Areas
- Operational Excellence

Backed by an industry-leading CGT team

Working under constantly evolving regulatory guidance, accessing dispersed patient populations, and leading long-term follow-up studies and registries takes a team with equal parts skill and passion. With us, you have a partner with access to the experience and expertise to put your CGT on a clear path to changing lives.

100+
regulatory and market access consultants and strategists

700+
clinical and real-world data management staff globally

2,900+
clinical operations staff

600+
multidisciplinary peri- and post-approval scientists globally

12+
hours of formalized, comprehensive training for all CGT staff

Put our 20+ years of CGT experience to work for you.

Let's go →

Evidera | PPD